Your cart is currently empty!
Tiffin, Iowa, USA, and Mysuru, Karnataka, India — July 7, 2025 — ORF Biologics, Inc., a U.S.-based biotechnology firm specializing in recombinant protein expression and assay development, and Vipragen Biosciences Pvt. Ltd., a leading preclinical contract research organization (CRO) in India, are pleased to announce a strategic business partnership aimed at accelerating innovation in drug discovery research and assay development.
This collaboration leverages ORF Biologics’ expertise in recombinant protein technologies and Vipragen’s comprehensive capabilities in early discovery and preclinical research, including GLP-compliant bioanalytical services, immunogenicity testing, and biomarker identification. Together, the companies aim to develop robust, regulatory-compliant assays and provide consultancy services. The companies collective aim is to enhance scientific research and navigate the regulatory hurdles for compliant assay development for biologics, biosimilars, and novel therapeutics.
“Partnering with Vipragen allows us to expand our assay development capabilities and offer our clients a more comprehensive suite of services,” said Anant Kamath, CEO of ORF Biologics, Inc. “Their state-of-the-art facilities and experienced scientific team make them an ideal collaborator in our mission to advance biologics research.”
Vipragen Biosciences, established in 2012, offers a wide range of services, including primary and secondary pharmacology models, ADME, pharmacokinetics, toxicology, toxicokinetics and analytical testing, adhering to international regulatory standards such as OECD GLP, AAALAC, and NABL accreditations. Their expertise in bioanalytical method development and validation, as well as immunogenicity assays, will complement ORF Biologics’ strengths in recombinant protein expression and assay development.
“We are excited to collaborate with ORF Biologics to enhance our assay development offerings and provide comprehensive support to clients in the biologics sector,” said Yashas Chandra, Executive Director of Vipragen Biosciences Pvt. Ltd. “This partnership aligns with our commitment to delivering high-quality, regulatory-compliant research services to the global pharmaceutical and biotechnology companies.”
About ORF Biologics, Inc.
ORF Biologics, Inc., headquartered in Tiffin, Iowa, specializes in the expression of recombinant proteins and the development of assays for biologics research. The company is dedicated to advancing scientific discovery through innovative solutions and collaborative partnerships.
About Vipragen Biosciences Pvt. Ltd.
Vipragen Biosciences Pvt. Ltd., based in Mysuru, Karnataka, India, is an integrated preclinical CRO offering a comprehensive range of services, including toxicology, pharmacokinetics, and analytical testing. With a focus on quality and compliance, Vipragen supports clients in the pharmaceutical, biotechnology, and related industries.
Contact Information
ORF Biologics, Inc.
1110 Tall Grass Avenue
Tiffin, Iowa 52340, USA
Email: contact@orfbiologics.com
Website: www.orfbiologics.com
Vipragen Biosciences Pvt. Ltd.
No. 67B, Hootagalli Industrial Area
Mysore – 570018, India
Contact Person: Yashas Chandra, Executive Director
Email: yashas.c@vipragen.com Website: www.vipragen.com